Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

CardioDx's Gene Expression Test for the Assessment of Obstructive Coronary Artery Disease

Published: Tuesday, July 31, 2012
Last Updated: Tuesday, July 31, 2012
Bookmark and Share
Corus CAD offers an accurate, non-invasive approach beyond traditional methods.

CardioDx, Inc. announced online publication of a study in the American Heart Journal. The paper, titled "A Gender Specific Blood-Based Gene Expression Score for Assessing Obstructive Coronary Artery Disease in Non-Diabetic Patients: Results of the PREDICT Trial," reported the performance of the company's Corus(R) CAD gene expression test for the assessment of obstructive coronary artery disease (CAD) in men and women presenting with typical and atypical symptoms suggestive of obstructive CAD. The article is in press (available online now) and will appear in the September issue of the journal.

"Corus CAD is unique as it is the only gender-specific diagnostic test currently available that accurately risk stratifies patients with obstructive coronary artery disease, accounting for key biological differences between men and women," said Alexandra Lansky, M.D., Associate Professor of Medicine and Director of the Cardiovascular Research Center at Yale University School of Medicine, who is the lead author of the study. "This study found that commonly used diagnostic approaches, including symptom evaluation and myocardial perfusion imaging, performed less well in women than in men for identifying obstructive coronary artery disease. In contrast, the Corus CAD test performed well in both women and men. Corus CAD offers a reliable diagnostic approach for the assessment of non-diabetic patients, particularly women, with suspected obstructive coronary artery disease."

The study analyzed clinical data from 1,160 patients (58% men and 42% women) enrolled in the PREDICT trial, a prospective, multicenter study designed to develop and validate the Corus CAD test. All patients enrolled in PREDICT had been referred for elective invasive coronary angiography. The patients were classified as cases or controls based on an assessment of obstructive CAD by quantitative coronary angiography (QCA). Data from the QCA analysis was then compared to the blood-based Corus CAD test results to determine test performance. Eric Topol, M.D., Director of the Scripps Translational Science Institute in La Jolla, Calif., was the principal investigator for the trial.

The results of the analysis showed that Corus CAD test scores were significantly correlated with obstructive coronary artery disease in both male and female cohorts in PREDICT. The Corus CAD score was significantly and independently associated with obstructive CAD in both men and women, while symptoms of typical angina were significantly associated with obstructive CAD only for men (p<0.001). Each 10-point increase in the Corus CAD score was associated with a twofold increase in the likelihood of obstructive disease in men and women, as well as with an increase in maximum percent stenosis, number of lesions, and total coronary plaque volume. Higher Corus CAD scores were significantly associated with increased likelihood of disease in the overall population and in the male and female subgroups separately (all p=0.001), whereas commonly used myocardial perfusion imaging was not.

Women often have non-specific, atypical symptoms of CAD that make the assessment of CAD disease more difficult. Traditional diagnostic methods such as cardiac imaging do not account for gender-specific factors, and the real-world performance of these diagnostic tools is often compromised in women. In addition, many traditional tests involve radiation exposure, and cumulative effective doses of radiation from imaging procedures have been shown to be higher in women than in men.

A study published in the March 11, 2010 issue of The New England Journal of Medicine found that in nearly 400,000 patients who underwent elective invasive angiographic procedures, 62 percent were found to have no obstructive coronary artery blockage, despite the fact that the majority of patients (84 percent) had received noninvasive diagnostic tests prior to referral to catheterization. The authors concluded that current modalities for identifying which patients should undergo elective invasive coronary angiography to diagnose obstructive CAD have limitations, and that better methods are needed for patient risk stratification. Typical and atypical presentations of stable chest pain account for up to two percent of all doctor's office visits each year, or as many as 10,000 patients every day in the U.S.

"Traditional tests for obstructive coronary artery disease result in many cardiac catheterizations where no disease is found, especially in women," said Mark Monane, M.D., Chief Medical Officer of CardioDx. "This analysis from the PREDICT trial adds to the clinical evidence demonstrating that the Corus CAD test can accurately and non-invasively help clinicians identify whether or not patients need further diagnostic cardiac evaluation, enabling many patients to avoid unnecessary testing and exposure to radiation risks or imaging agent intolerance."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Cancer Genetics: Key to Diagnosis, Therapy
When applied judiciously, cancer genetics directs caregivers to the right drug at the right time, while sparing patients of unnecessary or harmful treatments.
Accelerating the Detection of Foodborne Bacterial Outbreaks
The speed of diagnosis of foodborne bacterial outbreaks could be improved by a new technique developed by researchers at the Georgia Institute of Technology.
Cancer Gene Predicts Treatment Response in Leukaemia
Study indicates the patients suffering from a lethal for of acute myeloid leukemia may live longer when receiving milder chemotherapy drugs.
New Diagnostic Tool for Familial Mediterranean Fever
A new tool developed by researchers at VIB and Ghent University could improve the process of diagnosing Familial Mediterranean Fever.
'Lab on the Skin' for Sweat Analysis
Northwestern University researchers develop a low-cost wearable electronic device that collects and analyzes sweat for health monitoring.
Molecular Signature for Aggressive Brain Tumor Uncovered
Researchers have identified genetic mutations in a highly agressive brain cancer that distinguishes the agressive, from the benign forms of the cancer.
Malaria Parasite Evades Rapid Test Detection in Children
A study at the University of North Carolina found that gene deletion poses a threat to Malaria eradication efforts.
Novel Urine Test to Predict High-Risk Cervical Cancer
Preliminary studies affirm accuracy and potential cost savings to screen for virus-caused malignancy.
GFC Diagnostics Wins Longitude Prize Discovery Award
The global award was won for the development of a cheap, quick and simple MRSA Test.
Understanding Circulating Tumour Cells
Research team develops new tool to track traveling cancer cells in the bloodstream.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!